Big Shot: Developments in Prefilled Syringes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Big Shot: Developments in Prefilled Syringes
Many companies are coming up with innovative materials and manufacturing methods to feed the growing demand for prefilled syringes.


Pharmaceutical Technology


Less overfill. One of the greatest benefits is the significant reduction in the amount of product needed to overfill the container. "By using a prefilled syringe, 10, 15, sometimes even 20% of the API can be saved," Zimmerman notes. "With this all-in-one solution, there is no substance loss through refilling. We've had customers that converted from vial to prefilled syringe that were able to scale down their API process because they didn't need as much," Zimmerman continues.

Overfill for a prefilled syringe is significantly less—in the single digits, according to Cory Lewis, director of new business development with Baxter BioPharma Solutions (Bloomington, IN). "When you're talking about bulk drug API that's in the thousands of dollars per gram, there is a true economic savings that companies can yield," he says. A BD study indicated a potential for up to 23% more product dose yield in a prefill compared with a vial, as less product is lost in the transfer from a vial to a syringe.

Design

Glass and plastic. Although plastic prefilled syringes are gaining in popularity in Europe, glass barrels are still preferred in the United States: 99% of the prefillable syringes sold in the US by BD are its Hypak prefillable glass syringe. Glass is heavily favored, primarily because it has been part of the industry for a long period of time.

"The real problem with the plastic is that it is less well known and less well characterized. Glass has been around as a container for drugs since the Egyptian empire," Michael Eakins points out.

Glass prefilled syringes are made of Type I borosilicate glass, the same type that has been used for vials for a long time. The downside to using glass, however, also is well known: Glass contains alkali ions, which can lead to a surface reaction that forms a small amount of sodium hydroxide. After years of observing this effect in glass vials, most pharma companies know what to expect and have devised ways to get around the problem.

Until recently, plastics were not as clear as glass, making it difficult for companies to visually inspect their products for particulates. But recently, more companies have taken an interest in plastics, mainly owing to recent advances in their design and makeup. Original plastic syringes, which were introduced in the early 1990s, were made from polypropylene. Several companies now offer syringe barrels made of cyclic olefin polymer or cyclic olefin copolymer, which is as clear as glass but less heavy and less likely to break. Cyclic olefin plastics also are more resistant than polypropylene to water transmission, which may help lengthen the shelf life of the drug product.

BD, West Pharmaceuticals, and Baxter BioPharma are all developing plastics for prefillable syringes. In 2000, BD launched a plastic prefillable syringe system known as "BD Sterifill SCF," which is transparent, resistant to breakage, and lightweight. Sterifill is composed of BD's "Crystal Clear Polymer," an amorphous, high-performance polycycloolefin. The company also has released its "BD Uniject" single-use, auto-disable prefill injection device, which contains a small, blister reservoir filled with the drug attached to the needle. Squeezing the reservoir releases the drug.

West's Resin Crystal Zenith (CZ) silicone-free syringe system is made of cyclic polyolefin and has high heat resistance and low temperature characteristics. It is also break-resistant and clear.

Awaiting approval is Baxter's most recent development, "Clearshot," which, like Sterifill and CZ, is break resistant, lightweight, and offers high clarity. The process used to produce Clearshot is somewhat unique: the syringe is formed, processed, and sterilized inline. "We start off with a resin pellet and at the end of the line comes a syringe with the drug product, stoppered," says Cory Lewis.

Plastics have a ways to go before they're widely accepted in the pharmaceutical industry, but as more companies produce purer, more glass-like plastics, plastic syringes begin to gain ground. "There has been much more interest in plastics," notes Eakins. "It's quite clear the interest is increasing."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here